Literature DB >> 29477084

Differences in time to injection onset by drug in California: Implications for the emerging heroin epidemic.

Ricky N Bluthenthal1, Daniel Chu2, Lynn D Wenger3, Philippe Bourgois4, Thomas Valente2, Alex H Kral3.   

Abstract

BACKGROUND: Heroin use is increasing in the US. Heroin use may predispose users towards injection routes of drug administration as compared to other illicit substances.
OBJECTIVE: To explore the relationship between heroin use and drug injection, we compared time from first use to first injection (referred to as time to injection onset by drug [TTIOD]) of heroin, methamphetamine/speed, cocaine, and crack cocaine among people who inject drugs (PWID).
METHODS: Age of first use and first injection by drug was collected from 776 PWID. Survival analyses were used to determine TTIOD and to examine demographic factors associated with TTIOD. Cox regression analysis was used to determine demographic factors associated with drug-specific injection onset.
RESULTS: The eventual injection onset rate by the drug was 99% for participants who used heroin, 85% for participants who used methamphetamine/speed, 80% for participants who used powder cocaine, and 38% for participants who used crack cocaine. Hazard ratios for injection use within one year of first use by drug were: 1.37 (median survival time [MST] = 0.61 years) for heroin, 0.66 (MST = 1.10 years) for methamphetamine/speed, 0.50 (MST = 2.93 years) for powder cocaine, and 0.12 (MST = 39.59 years) for crack cocaine. Demographic differences in TTIOD were found for each drug. Demographic differences were found for eventual injection by drug for all substances except heroin.
CONCLUSION: Among PWID, heroin use was associated with a more rapid transition to injection and a higher rate of eventual heroin injection regardless of demographics. More robust, innovative efforts to reduce heroin use and prevent injection initiation are urgently needed.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Epidemiology; Heroin; Injection drugs; PWID; Time to injection onset

Mesh:

Substances:

Year:  2018        PMID: 29477084      PMCID: PMC5889717          DOI: 10.1016/j.drugalcdep.2018.01.005

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  69 in total

1.  Effects of drug treatment for heroin sniffers: a protective factor against moving to injection?

Authors:  Margaret S Kelley; Dale D Chitwood
Journal:  Soc Sci Med       Date:  2004-05       Impact factor: 4.634

2.  Needle fixation, the drug user's perspective: a qualitative study.

Authors:  A J McBride; R M Pates; K Arnold; N Ball
Journal:  Addiction       Date:  2001-07       Impact factor: 6.526

Review 3.  Methamphetamine use in urban gay and bisexual populations.

Authors:  Steven Shoptaw
Journal:  Top HIV Med       Date:  2006 Jun-Jul

Review 4.  Opioid epidemic in the United States.

Authors:  Laxmaiah Manchikanti; Standiford Helm; Bert Fellows; Jeffrey W Janata; Vidyasagar Pampati; Jay S Grider; Mark V Boswell
Journal:  Pain Physician       Date:  2012-07       Impact factor: 4.965

5.  Hepatitis C virus infection among adolescents and young adults:Massachusetts, 2002-2009.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2011-05-06       Impact factor: 17.586

6.  Moral ambivalence and the decision to initiate others into injection drug use: A qualitative study in two California cities.

Authors:  Lynn D Wenger; Andrea M Lopez; Alex H Kral; Ricky N Bluthenthal
Journal:  Int J Drug Policy       Date:  2016-07-30

7.  Initiation Stories: An Examination of the Narratives of People Who Assist With a First Injection.

Authors:  Gillian Kolla; Carol Strike; Élise Roy; Jason Altenberg; Raffi Balian; Rey Silver; Neil Hunt
Journal:  Subst Use Misuse       Date:  2015-11-23       Impact factor: 2.164

8.  Community-based opioid overdose prevention programs providing naloxone - United States, 2010.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2012-02-17       Impact factor: 17.586

9.  Pathways to HIV risk and vulnerability among lesbian, gay, bisexual, and transgendered methamphetamine users: a multi-cohort gender-based analysis.

Authors:  Brandon D L Marshall; Evan Wood; Jean A Shoveller; Thomas L Patterson; Julio S G Montaner; Thomas Kerr
Journal:  BMC Public Health       Date:  2011-01-07       Impact factor: 3.295

10.  Vital Signs: Demographic and Substance Use Trends Among Heroin Users - United States, 2002-2013.

Authors:  Christopher M Jones; Joseph Logan; R Matthew Gladden; Michele K Bohm
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2015-07-10       Impact factor: 17.586

View more
  4 in total

1.  Cost-effectiveness of Direct Antiviral Agents for Hepatitis C Virus Infection and a Combined Intervention of Syringe Access and Medication-assisted Therapy for Opioid Use Disorders in an Injection Drug Use Population.

Authors:  Elizabeth R Stevens; Kimberly A Nucifora; Holly Hagan; Ashly E Jordan; Jennifer Uyei; Bilal Khan; Kirk Dombrowski; Don des Jarlais; R Scott Braithwaite
Journal:  Clin Infect Dis       Date:  2020-06-10       Impact factor: 9.079

2.  Factors Associated with Frequency of Recent Initiation of Others into Injection Drug Use Among People Who Inject Drugs in Los Angeles and San Francisco, CA, USA, 2016-17.

Authors:  Stephanie Navarro; Alex H Kral; Carol S Strike; Kelsey Simpson; Lynn Wenger; Ricky N Bluthenthal
Journal:  Subst Use Misuse       Date:  2019-05-03       Impact factor: 2.164

3.  Associations between perceived illicit fentanyl use and infectious disease risks among people who inject drugs.

Authors:  Barrot H Lambdin; Ricky N Bluthenthal; Jon E Zibbell; Lynn Wenger; Kelsey Simpson; Alex H Kral
Journal:  Int J Drug Policy       Date:  2019-11-13

4.  Under the Skin: The Relationship Between Subcutaneous Injection and Skin Infections Among People Who Inject Drugs.

Authors:  Christina E Freibott; Kristina T Phillips; Bradley J Anderson; Catherine Stewart; Jane M Liebschutz; Michael D Stein
Journal:  J Addict Med       Date:  2022 Mar-Apr 01       Impact factor: 3.702

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.